A refined concept: α-synuclein dysregulation disease

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Alpha-synuclein (αSyn) aggregation is central to synucleinopathies, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA).
• Despite identifying the SNCA gene's role in familial PD, αSyn's precise pathological mechanisms remain incompletely understood.
• Emerging therapies target reducing αSyn levels and aggregates, but clinical success is hindered by the difficulty of treating advanced neurodegeneration.

Purpose of the Study:

• To propose a refined concept for defining the early pathogenic state of αSyn accumulation.
• To establish a disease criterion for αSyn dysregulation that precedes observable brain damage.
• To advocate for prodromal intervention strategies targeting pre-symptomatic αSyn pathology.

Main Methods:

• Review of current literature on αSyn biology, synucleinopathies, and therapeutic strategies.
• Analysis of challenges in treating neurodegenerative diseases, drawing parallels with Alzheimer's disease clinical trial outcomes.
• Conceptual framework development for defining early pathogenic αSyn states.

Main Results:

• Current therapeutic approaches face challenges due to late-stage diagnosis and irreversible brain damage.
• Prodromal intervention holds promise but faces ethical and practical hurdles for pre-symptomatic treatment.
• A refined definition of early pathogenic αSyn accumulation is needed to guide therapeutic development.

Conclusions:

• Defining an early pathogenic state of αSyn accumulation is crucial for effective therapeutic intervention in synucleinopathies.
• This conceptual shift could enable earlier treatment, potentially improving patient outcomes.
• Further research is needed to validate and implement this early disease criterion for clinical practice.